Cochlear Limited

Equities

COH

AU000000COH5

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
320 ^AUD	-0.90%		+1.66%	+7.14%

Apr. 22	Cochlear Limited Announces Company Secretary Changes	CI
Apr. 19	Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old	CI

Cochlear Limited Updates Earnings Guidance for the Fiscal 2020

March 15, 2020 at 06:51 pm EDT

Cochlear Limited updated earnings guidance for the fiscal 2020. The company is not in a position to provide an earnings outlook to the market at this time and withdraw its earnings guidance for fiscal 2020.

Latest news about Cochlear Limited

Cochlear Limited Announces Company Secretary Changes	Apr. 21	CI
Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old	Apr. 19	CI
Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business	Apr. 03	MT
Miners, healthcare firms push Australia stocks higher	Mar. 25	RE
Sensorion: study results in hearing loss	Mar. 11	CF
Morgan Stanley Adjusts Cochlear’s Price Target to AU$276 From AU$258, Keeps at Underweight	Mar. 05	MT
Jarden Research Adjusts Cochlear’s Price Target to AU$244.35 From AU$237.17, Keeps at Neutral	Feb. 19	MT
Cochlear's Revenue Soars on Sales Growth	Feb. 19	MT
Australian Shares Flat as Mining, Financials Rally Offset Other Sectors' Losses	Feb. 19	MT
Cochlear Shares Slip 2%; Expects 26% Rise in Full Year Net Profit After Increase in H1 FY24 Profit, Revenue	Feb. 18	MT
Transcript : Cochlear Limited, H1 2024 Earnings Call, Feb 19, 2024	Feb. 18
Cochlear Posts Rise in H1 FY24 Profit, Revenue	Feb. 18	MT
Correction: --Cochlear Reports Half Year FY24 Revenue Up 24% to AU$1.1 Billion; EPS of AU$2.913	Feb. 18	MT
Cochlear Reports Half Year FY24 Revenue Up Down 24% to AU$1.1 Billion; EPS of AU$2.913	Feb. 18	MT
Tranche Update on Cochlear Limited's Equity Buyback Plan announced on February 15, 2023.	Feb. 18	CI
Cochlear Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 18	CI
Cyclopharm Appoints CFO; Shares Rise 3%	Feb. 12	MT
Australia shares slip as biotech firm CSL slumps on failed drug trial (Feb 12)	Feb. 11	RE
Australian shares post first weekly fall in three as rate-hike bets back in focus	Feb. 09	RE
Jarden Research Adjusts Cochlear's Price Target to AU$237.17 From AU$229.20, Keeps at Neutral	Feb. 09	MT
Cochlear Upgrades Fiscal 2024 Profit Guidance; Shares Up 5%	Feb. 07	MT
Transcript : Cochlear Limited - Analyst/Investor Day	23-10-26
Transcript : Cochlear Limited - Shareholder/Analyst Call	23-10-16
Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns	23-10-12	RE
European Commission OKs Cochlear's Aquisition of Oticon Medical Unit	23-10-10	MT

Chart Cochlear Limited

Duration

Period

More charts

Company Profile

Cochlear Limited is an Australia-based company, which provides implantable hearing solutions and sound processors. The Company is engaged in development, manufacture and commercialization of implantable hearing solutions. Its segments include Cochlear implants, Services (sound processor upgrades and other) and Acoustics. The Companyâs products and services portfolio include Cochlear implant portfolio, Acoustic solutions portfolio, and Recipient support tools. Its Cochlear Connected Care solutions include Cochlear Nucleus SmartNav System, Cochlear Custom Sound Pro Fitting Software, Cochlear Link, Cochlear Remote Assist, and Cochlear Remote Check solution for cochlear implants. Its Cochlear implant portfolio include Cochlear Nucleus System. Its Acoustic solutions portfolio include Cochlear Osia System, and Cochlear Baha System. Its Recipient support tools include Cochlear Nucleus, Baha and Osia Smart Apps and Cochlear CoPilot App.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-14 - Q4 2024 Earnings Release

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for Cochlear Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

320 AUD

Average target price

280.9 AUD

Spread / Average Target

-12.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Prosthetics

	1st Jan change	Capi.
COCHLEAR LIMITED	+7.14%	13.7B
STRAUMANN HOLDING AG	+1.11%	23.96B
SONOVA HOLDING AG	-7.00%	16.71B
DEMANT A/S	+8.38%	10.08B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-19.75%	2.03B
EMBLA MEDICAL HF.	+12.20%	1.88B
ANGELALIGN TECHNOLOGY INC.	+36.69%	1.6B
ANGEL ROBOTICS CO., LTD.	0.00%	495M
DELCATH SYSTEMS, INC.	+30.29%	142M
INTEGRUM AB	+34.50%	106M

Medical Prosthetics